CAPRELSA®( vandetanib )

Drug CAPRELSA® vandetanib Caprelsa Overview This is a summary of the European public assessment report (EPAR) for Caprelsa. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Caprelsa. How is Caprelsa used? […]

ADCETRIS® (brentuximab vedotin)

Drug ADCETRIS® brentuximab vedotin Adcetris Overview Adcetris is a cancer medicine used to treat adults with Hodgkin’s lymphoma (HL, a type of cancer that originates from blood cells in the lymphatic system, a part of the immune system). Adcetris is used when the tumour cells are CD30-positive (when they have a protein called CD30 on […]

INTRON A® (interferon alfa-2b)

Drug INTRON A® interferon alfa-2b intron A Overview This is a summary of the European public assessment report (EPAR) for IntronA. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for IntronA. How is Intron A […]

ATRIANCE® (nelarabine)

Drug ATRIANCE® nelarabine Atriance Overview This is a summary of the European public assessment report (EPAR) for Atriance. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Atriance.   How is Atriance used? Atriance is […]

CAELYX® (doxorubicin)

Drug CAELYX® doxorubicin  Caelyx Overview This is a summary of the European public assessment report (EPAR) for Caelyx. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Caelyx. How is Caelyx used? Caelyx should be […]

KYMRIAH® (tisagenlecleucel)

Drug KYMRIAH® Tisagenlecleucel Kymriah Overview Kymriah is a medicine for treating two types of blood cancer: B-cell acute lymphoblastic leukaemia (ALL), in children and young adults up to 25 years of age whose cancer did not respond to previous treatment, has come back two or more times, or has come back after a transplant of […]

IMBRUVICA® (ibrutinib)

Drug IMBRUVICA® Ibrutinib Imbruvica Overview Imbruvica is a medicine for treating adult patients with the following blood cancers: chronic lymphocytic leukaemia (CLL) in previously untreated patients and in patients who have received at least one previous treatment; mantle cell lymphoma in patients whose disease does not respond to or has come back after previous treatment; […]

YESCARTA® (axicabtagene ciloleucel)

Drug YESCARTA® axicabtagene ciloleucel Yescarta Overview Yescarta is a medicine for treating two types of blood cancer: diffuse large B-cell lymphoma (DLBCL); primary mediastinal large B-cell lymphoma (PMBCL). Yescarta is for adult patients whose blood cancer has returned or has stopped responding to previous treatment. Yescarta is a type of advanced therapy medicine called a […]

KEYTRUDA® (pembrolizumab)

Drug KEYTRUDA® Pembrolizumab Keytruda Overview Keytruda is a cancer medicine used to treat: melanoma, a skin cancer, non-small cell lung cancer (NSCLC), a type of lung cancer, classical Hodgkin lymphoma, a cancer of the white blood cells, urothelial cancer, a cancer of the bladder and urinary tract, a cancer affecting the head and neck known […]